Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610515 | 1.00 | GPR52 (0.41) | GPR52ALOX15ALDH1A1CYP3A4TDP1 | |
| SCHEMBL21482617 | 0.83 | ESR1 (0.46) | ALOX15ALDH1A1CYP3A4TDP1CYP2C19 | |
| SCHEMBL31303616 | 0.83 | POLB (0.40) | GPR52ALOX15ALDH1A1CYP3A4TDP1 | |
| SCHEMBL11660253 | 0.81 | FDPS (0.41) | GPR52ALOX15ALDH1A1TDP1NPC1 | |
| SCHEMBL11293428 | 0.81 | MEN1 (0.47) | GPR52ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL31303591 | 0.80 | SLC6A2 (0.37) | GPR52ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL6569517 | 0.80 | CYP2C9 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL5419014 | 0.80 | AOC3 (0.41) | ALOX15ALDH1A1CYP3A4TDP1CYP2C9 | |
| SCHEMBL13432000 | 0.79 | MAPT (0.47) | ALDH1A1CYP3A4TDP1CYP2C9CYP2C19 | |
| SCHEMBL10898372 | 0.79 | ALDH1A1 (0.45) | GPR52ALDH1A1CYP2C19NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-03 | — | — | US | disclosed |
| WO-2019199667-A2 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | KEANEY GREGG F (US) | 2019-10-17 | — | — | WO | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | GPR52 4250/4885ALOX15 515/4885ALDH1A1 3225/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | GPR52 2760/4885ALOX15 69/4885ALDH1A1 2637/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | GPR52 2969/4885ALOX15 377/4885ALDH1A1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.